nodes	percent_of_prediction	percent_of_DWPC	metapath
Amoxapine—HTR2B—Sorafenib—liver cancer	0.35	0.509	CbGbCtD
Amoxapine—HTR2C—Sorafenib—liver cancer	0.228	0.331	CbGbCtD
Amoxapine—CYP2D6—Sorafenib—liver cancer	0.0683	0.0993	CbGbCtD
Amoxapine—CYP2D6—Doxorubicin—liver cancer	0.0415	0.0603	CbGbCtD
Amoxapine—Gynaecomastia—Sorafenib—liver cancer	0.00315	0.0257	CcSEcCtD
Amoxapine—Lacrimation—Epirubicin—liver cancer	0.00221	0.0181	CcSEcCtD
Amoxapine—Pancreatitis—Sorafenib—liver cancer	0.00217	0.0177	CcSEcCtD
Amoxapine—Lacrimation—Doxorubicin—liver cancer	0.00205	0.0167	CcSEcCtD
Amoxapine—Erectile dysfunction—Sorafenib—liver cancer	0.00204	0.0166	CcSEcCtD
Amoxapine—Acute coronary syndrome—Sorafenib—liver cancer	0.00194	0.0159	CcSEcCtD
Amoxapine—Myocardial infarction—Sorafenib—liver cancer	0.00193	0.0158	CcSEcCtD
Amoxapine—Stomatitis—Sorafenib—liver cancer	0.00192	0.0157	CcSEcCtD
Amoxapine—Jaundice—Sorafenib—liver cancer	0.00192	0.0157	CcSEcCtD
Amoxapine—Tinnitus—Sorafenib—liver cancer	0.00165	0.0135	CcSEcCtD
Amoxapine—Petechiae—Epirubicin—liver cancer	0.00158	0.0129	CcSEcCtD
Amoxapine—Alopecia—Sorafenib—liver cancer	0.00156	0.0128	CcSEcCtD
Amoxapine—Dysgeusia—Sorafenib—liver cancer	0.00151	0.0123	CcSEcCtD
Amoxapine—Petechiae—Doxorubicin—liver cancer	0.00146	0.012	CcSEcCtD
Amoxapine—Lacrimation increased—Epirubicin—liver cancer	0.00141	0.0115	CcSEcCtD
Amoxapine—Syncope—Sorafenib—liver cancer	0.00138	0.0113	CcSEcCtD
Amoxapine—Leukopenia—Sorafenib—liver cancer	0.00138	0.0113	CcSEcCtD
Amoxapine—Loss of consciousness—Sorafenib—liver cancer	0.00135	0.0111	CcSEcCtD
Amoxapine—Atrioventricular block—Epirubicin—liver cancer	0.00134	0.011	CcSEcCtD
Amoxapine—Hypertension—Sorafenib—liver cancer	0.00133	0.0109	CcSEcCtD
Amoxapine—Coordination abnormal—Epirubicin—liver cancer	0.00133	0.0108	CcSEcCtD
Amoxapine—Lacrimation increased—Doxorubicin—liver cancer	0.00131	0.0107	CcSEcCtD
Amoxapine—Dry mouth—Sorafenib—liver cancer	0.00128	0.0105	CcSEcCtD
Amoxapine—Atrioventricular block—Doxorubicin—liver cancer	0.00124	0.0101	CcSEcCtD
Amoxapine—Shock—Sorafenib—liver cancer	0.00124	0.0101	CcSEcCtD
Amoxapine—Thrombocytopenia—Sorafenib—liver cancer	0.00123	0.0101	CcSEcCtD
Amoxapine—Coordination abnormal—Doxorubicin—liver cancer	0.00123	0.01	CcSEcCtD
Amoxapine—Anorexia—Sorafenib—liver cancer	0.0012	0.00978	CcSEcCtD
Amoxapine—Mental disability—Epirubicin—liver cancer	0.00113	0.00923	CcSEcCtD
Amoxapine—Dyspepsia—Sorafenib—liver cancer	0.00111	0.00904	CcSEcCtD
Amoxapine—Decreased appetite—Sorafenib—liver cancer	0.00109	0.00892	CcSEcCtD
Amoxapine—Fatigue—Sorafenib—liver cancer	0.00108	0.00885	CcSEcCtD
Amoxapine—Constipation—Sorafenib—liver cancer	0.00107	0.00878	CcSEcCtD
Amoxapine—Vascular purpura—Epirubicin—liver cancer	0.00106	0.00863	CcSEcCtD
Amoxapine—Mental disability—Doxorubicin—liver cancer	0.00105	0.00854	CcSEcCtD
Amoxapine—Gastrointestinal pain—Sorafenib—liver cancer	0.00103	0.00839	CcSEcCtD
Amoxapine—Increased appetite—Epirubicin—liver cancer	0.00101	0.00822	CcSEcCtD
Amoxapine—Urticaria—Sorafenib—liver cancer	0.000998	0.00815	CcSEcCtD
Amoxapine—Abdominal pain—Sorafenib—liver cancer	0.000993	0.00811	CcSEcCtD
Amoxapine—Body temperature increased—Sorafenib—liver cancer	0.000993	0.00811	CcSEcCtD
Amoxapine—Purpura—Epirubicin—liver cancer	0.00098	0.00801	CcSEcCtD
Amoxapine—Vascular purpura—Doxorubicin—liver cancer	0.000977	0.00798	CcSEcCtD
Amoxapine—Cerebrovascular accident—Epirubicin—liver cancer	0.000964	0.00788	CcSEcCtD
Amoxapine—Increased appetite—Doxorubicin—liver cancer	0.000931	0.0076	CcSEcCtD
Amoxapine—Purpura—Doxorubicin—liver cancer	0.000907	0.00741	CcSEcCtD
Amoxapine—Asthenia—Sorafenib—liver cancer	0.000902	0.00736	CcSEcCtD
Amoxapine—Cerebrovascular accident—Doxorubicin—liver cancer	0.000892	0.00729	CcSEcCtD
Amoxapine—Pruritus—Sorafenib—liver cancer	0.000889	0.00726	CcSEcCtD
Amoxapine—Ataxia—Epirubicin—liver cancer	0.000889	0.00726	CcSEcCtD
Amoxapine—Diarrhoea—Sorafenib—liver cancer	0.00086	0.00702	CcSEcCtD
Amoxapine—Dizziness—Sorafenib—liver cancer	0.000831	0.00679	CcSEcCtD
Amoxapine—Ataxia—Doxorubicin—liver cancer	0.000822	0.00672	CcSEcCtD
Amoxapine—Eosinophilia—Epirubicin—liver cancer	0.000809	0.0066	CcSEcCtD
Amoxapine—Pancreatitis—Epirubicin—liver cancer	0.000801	0.00654	CcSEcCtD
Amoxapine—Vomiting—Sorafenib—liver cancer	0.000799	0.00653	CcSEcCtD
Amoxapine—Rash—Sorafenib—liver cancer	0.000792	0.00647	CcSEcCtD
Amoxapine—Dermatitis—Sorafenib—liver cancer	0.000792	0.00647	CcSEcCtD
Amoxapine—Headache—Sorafenib—liver cancer	0.000787	0.00643	CcSEcCtD
Amoxapine—Pollakiuria—Epirubicin—liver cancer	0.000754	0.00616	CcSEcCtD
Amoxapine—Eosinophilia—Doxorubicin—liver cancer	0.000748	0.00611	CcSEcCtD
Amoxapine—Nausea—Sorafenib—liver cancer	0.000746	0.0061	CcSEcCtD
Amoxapine—Weight increased—Epirubicin—liver cancer	0.000743	0.00607	CcSEcCtD
Amoxapine—Pancreatitis—Doxorubicin—liver cancer	0.000741	0.00605	CcSEcCtD
Amoxapine—Drowsiness—Epirubicin—liver cancer	0.000728	0.00595	CcSEcCtD
Amoxapine—Jaundice—Epirubicin—liver cancer	0.00071	0.0058	CcSEcCtD
Amoxapine—Stomatitis—Epirubicin—liver cancer	0.00071	0.0058	CcSEcCtD
Amoxapine—Pollakiuria—Doxorubicin—liver cancer	0.000698	0.0057	CcSEcCtD
Amoxapine—Weight increased—Doxorubicin—liver cancer	0.000688	0.00562	CcSEcCtD
Amoxapine—Agranulocytosis—Epirubicin—liver cancer	0.00068	0.00555	CcSEcCtD
Amoxapine—Drowsiness—Doxorubicin—liver cancer	0.000674	0.0055	CcSEcCtD
Amoxapine—Jaundice—Doxorubicin—liver cancer	0.000657	0.00536	CcSEcCtD
Amoxapine—Stomatitis—Doxorubicin—liver cancer	0.000657	0.00536	CcSEcCtD
Amoxapine—Hepatitis—Epirubicin—liver cancer	0.000654	0.00534	CcSEcCtD
Amoxapine—Hypoaesthesia—Epirubicin—liver cancer	0.00065	0.00531	CcSEcCtD
Amoxapine—Agranulocytosis—Doxorubicin—liver cancer	0.000629	0.00514	CcSEcCtD
Amoxapine—Tinnitus—Epirubicin—liver cancer	0.00061	0.00498	CcSEcCtD
Amoxapine—Hepatitis—Doxorubicin—liver cancer	0.000605	0.00494	CcSEcCtD
Amoxapine—Hypoaesthesia—Doxorubicin—liver cancer	0.000602	0.00492	CcSEcCtD
Amoxapine—Alopecia—Epirubicin—liver cancer	0.000578	0.00472	CcSEcCtD
Amoxapine—Tinnitus—Doxorubicin—liver cancer	0.000564	0.00461	CcSEcCtD
Amoxapine—Flatulence—Epirubicin—liver cancer	0.000561	0.00458	CcSEcCtD
Amoxapine—Tension—Epirubicin—liver cancer	0.000558	0.00456	CcSEcCtD
Amoxapine—Dysgeusia—Epirubicin—liver cancer	0.000557	0.00455	CcSEcCtD
Amoxapine—Nervousness—Epirubicin—liver cancer	0.000553	0.00451	CcSEcCtD
Amoxapine—Vision blurred—Epirubicin—liver cancer	0.000536	0.00438	CcSEcCtD
Amoxapine—Alopecia—Doxorubicin—liver cancer	0.000535	0.00437	CcSEcCtD
Amoxapine—Agitation—Epirubicin—liver cancer	0.000523	0.00427	CcSEcCtD
Amoxapine—Flatulence—Doxorubicin—liver cancer	0.000519	0.00424	CcSEcCtD
Amoxapine—Tension—Doxorubicin—liver cancer	0.000517	0.00422	CcSEcCtD
Amoxapine—Dysgeusia—Doxorubicin—liver cancer	0.000516	0.00421	CcSEcCtD
Amoxapine—Nervousness—Doxorubicin—liver cancer	0.000511	0.00418	CcSEcCtD
Amoxapine—Syncope—Epirubicin—liver cancer	0.00051	0.00417	CcSEcCtD
Amoxapine—Leukopenia—Epirubicin—liver cancer	0.000509	0.00416	CcSEcCtD
Amoxapine—Palpitations—Epirubicin—liver cancer	0.000503	0.00411	CcSEcCtD
Amoxapine—Loss of consciousness—Epirubicin—liver cancer	0.0005	0.00409	CcSEcCtD
Amoxapine—Vision blurred—Doxorubicin—liver cancer	0.000496	0.00405	CcSEcCtD
Amoxapine—Convulsion—Epirubicin—liver cancer	0.000493	0.00403	CcSEcCtD
Amoxapine—Hypertension—Epirubicin—liver cancer	0.000491	0.00401	CcSEcCtD
Amoxapine—Agitation—Doxorubicin—liver cancer	0.000484	0.00395	CcSEcCtD
Amoxapine—Dry mouth—Epirubicin—liver cancer	0.000474	0.00387	CcSEcCtD
Amoxapine—Syncope—Doxorubicin—liver cancer	0.000472	0.00386	CcSEcCtD
Amoxapine—Leukopenia—Doxorubicin—liver cancer	0.000471	0.00385	CcSEcCtD
Amoxapine—Confusional state—Epirubicin—liver cancer	0.000468	0.00382	CcSEcCtD
Amoxapine—Palpitations—Doxorubicin—liver cancer	0.000465	0.0038	CcSEcCtD
Amoxapine—Oedema—Epirubicin—liver cancer	0.000464	0.00379	CcSEcCtD
Amoxapine—Loss of consciousness—Doxorubicin—liver cancer	0.000463	0.00378	CcSEcCtD
Amoxapine—Shock—Epirubicin—liver cancer	0.000457	0.00373	CcSEcCtD
Amoxapine—Convulsion—Doxorubicin—liver cancer	0.000456	0.00373	CcSEcCtD
Amoxapine—Thrombocytopenia—Epirubicin—liver cancer	0.000455	0.00371	CcSEcCtD
Amoxapine—Hypertension—Doxorubicin—liver cancer	0.000455	0.00371	CcSEcCtD
Amoxapine—Tachycardia—Epirubicin—liver cancer	0.000453	0.0037	CcSEcCtD
Amoxapine—Anorexia—Epirubicin—liver cancer	0.000443	0.00362	CcSEcCtD
Amoxapine—Dry mouth—Doxorubicin—liver cancer	0.000438	0.00358	CcSEcCtD
Amoxapine—Hypotension—Epirubicin—liver cancer	0.000434	0.00354	CcSEcCtD
Amoxapine—Confusional state—Doxorubicin—liver cancer	0.000433	0.00354	CcSEcCtD
Amoxapine—Oedema—Doxorubicin—liver cancer	0.00043	0.00351	CcSEcCtD
Amoxapine—Shock—Doxorubicin—liver cancer	0.000423	0.00345	CcSEcCtD
Amoxapine—Thrombocytopenia—Doxorubicin—liver cancer	0.000421	0.00344	CcSEcCtD
Amoxapine—Insomnia—Epirubicin—liver cancer	0.00042	0.00343	CcSEcCtD
Amoxapine—Tachycardia—Doxorubicin—liver cancer	0.000419	0.00343	CcSEcCtD
Amoxapine—Paraesthesia—Epirubicin—liver cancer	0.000417	0.00341	CcSEcCtD
Amoxapine—Somnolence—Epirubicin—liver cancer	0.000413	0.00337	CcSEcCtD
Amoxapine—Anorexia—Doxorubicin—liver cancer	0.00041	0.00335	CcSEcCtD
Amoxapine—Dyspepsia—Epirubicin—liver cancer	0.000409	0.00334	CcSEcCtD
Amoxapine—Decreased appetite—Epirubicin—liver cancer	0.000404	0.0033	CcSEcCtD
Amoxapine—Hypotension—Doxorubicin—liver cancer	0.000402	0.00328	CcSEcCtD
Amoxapine—Fatigue—Epirubicin—liver cancer	0.0004	0.00327	CcSEcCtD
Amoxapine—Constipation—Epirubicin—liver cancer	0.000397	0.00324	CcSEcCtD
Amoxapine—Insomnia—Doxorubicin—liver cancer	0.000389	0.00317	CcSEcCtD
Amoxapine—Paraesthesia—Doxorubicin—liver cancer	0.000386	0.00315	CcSEcCtD
Amoxapine—Feeling abnormal—Epirubicin—liver cancer	0.000383	0.00313	CcSEcCtD
Amoxapine—Somnolence—Doxorubicin—liver cancer	0.000382	0.00312	CcSEcCtD
Amoxapine—Gastrointestinal pain—Epirubicin—liver cancer	0.00038	0.0031	CcSEcCtD
Amoxapine—Dyspepsia—Doxorubicin—liver cancer	0.000378	0.00309	CcSEcCtD
Amoxapine—Decreased appetite—Doxorubicin—liver cancer	0.000374	0.00305	CcSEcCtD
Amoxapine—Fatigue—Doxorubicin—liver cancer	0.000371	0.00303	CcSEcCtD
Amoxapine—Urticaria—Epirubicin—liver cancer	0.000369	0.00301	CcSEcCtD
Amoxapine—Constipation—Doxorubicin—liver cancer	0.000367	0.003	CcSEcCtD
Amoxapine—Abdominal pain—Epirubicin—liver cancer	0.000367	0.003	CcSEcCtD
Amoxapine—Body temperature increased—Epirubicin—liver cancer	0.000367	0.003	CcSEcCtD
Amoxapine—Feeling abnormal—Doxorubicin—liver cancer	0.000354	0.00289	CcSEcCtD
Amoxapine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000351	0.00287	CcSEcCtD
Amoxapine—Urticaria—Doxorubicin—liver cancer	0.000341	0.00279	CcSEcCtD
Amoxapine—Abdominal pain—Doxorubicin—liver cancer	0.00034	0.00277	CcSEcCtD
Amoxapine—Body temperature increased—Doxorubicin—liver cancer	0.00034	0.00277	CcSEcCtD
Amoxapine—Asthenia—Epirubicin—liver cancer	0.000333	0.00272	CcSEcCtD
Amoxapine—Pruritus—Epirubicin—liver cancer	0.000329	0.00268	CcSEcCtD
Amoxapine—Diarrhoea—Epirubicin—liver cancer	0.000318	0.0026	CcSEcCtD
Amoxapine—Asthenia—Doxorubicin—liver cancer	0.000308	0.00252	CcSEcCtD
Amoxapine—Dizziness—Epirubicin—liver cancer	0.000307	0.00251	CcSEcCtD
Amoxapine—Pruritus—Doxorubicin—liver cancer	0.000304	0.00248	CcSEcCtD
Amoxapine—Vomiting—Epirubicin—liver cancer	0.000295	0.00241	CcSEcCtD
Amoxapine—Diarrhoea—Doxorubicin—liver cancer	0.000294	0.0024	CcSEcCtD
Amoxapine—Rash—Epirubicin—liver cancer	0.000293	0.00239	CcSEcCtD
Amoxapine—Dermatitis—Epirubicin—liver cancer	0.000293	0.00239	CcSEcCtD
Amoxapine—Headache—Epirubicin—liver cancer	0.000291	0.00238	CcSEcCtD
Amoxapine—Dizziness—Doxorubicin—liver cancer	0.000284	0.00232	CcSEcCtD
Amoxapine—Nausea—Epirubicin—liver cancer	0.000276	0.00225	CcSEcCtD
Amoxapine—Vomiting—Doxorubicin—liver cancer	0.000273	0.00223	CcSEcCtD
Amoxapine—Rash—Doxorubicin—liver cancer	0.000271	0.00221	CcSEcCtD
Amoxapine—Dermatitis—Doxorubicin—liver cancer	0.000271	0.00221	CcSEcCtD
Amoxapine—Headache—Doxorubicin—liver cancer	0.000269	0.0022	CcSEcCtD
Amoxapine—Nausea—Doxorubicin—liver cancer	0.000255	0.00208	CcSEcCtD
Amoxapine—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	1.49e-05	7.85e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.49e-05	7.84e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CCND1—liver cancer	1.49e-05	7.83e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—PIK3CA—liver cancer	1.48e-05	7.83e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—JUN—liver cancer	1.48e-05	7.82e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—STAT3—liver cancer	1.48e-05	7.8e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	1.48e-05	7.8e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CTNNB1—liver cancer	1.48e-05	7.8e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—MYC—liver cancer	1.48e-05	7.79e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—RAF1—liver cancer	1.48e-05	7.78e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TGFB1—liver cancer	1.47e-05	7.77e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—RAF1—liver cancer	1.47e-05	7.77e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	1.47e-05	7.77e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.47e-05	7.76e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—RAF1—liver cancer	1.47e-05	7.74e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MTOR—liver cancer	1.46e-05	7.72e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PIK3CB—liver cancer	1.46e-05	7.72e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	1.46e-05	7.68e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—KRAS—liver cancer	1.45e-05	7.66e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MMP9—liver cancer	1.45e-05	7.65e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—RAF1—liver cancer	1.44e-05	7.62e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CDKN1A—liver cancer	1.44e-05	7.62e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.44e-05	7.61e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MTOR—liver cancer	1.44e-05	7.6e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.44e-05	7.6e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CB—liver cancer	1.44e-05	7.58e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MTOR—liver cancer	1.44e-05	7.58e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.44e-05	7.58e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MTOR—liver cancer	1.43e-05	7.56e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CB—liver cancer	1.43e-05	7.56e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—KRAS—liver cancer	1.43e-05	7.54e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MTOR—liver cancer	1.41e-05	7.44e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	1.41e-05	7.44e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MAPK8—liver cancer	1.41e-05	7.44e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—AKT1—liver cancer	1.41e-05	7.42e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.4e-05	7.4e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.4e-05	7.38e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—HRAS—liver cancer	1.4e-05	7.37e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MYC—liver cancer	1.39e-05	7.35e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TGFB1—liver cancer	1.39e-05	7.33e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.38e-05	7.26e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CDKN1B—liver cancer	1.37e-05	7.25e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MYC—liver cancer	1.37e-05	7.25e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—PIK3CA—liver cancer	1.37e-05	7.24e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—HRAS—liver cancer	1.37e-05	7.24e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—PIK3CA—liver cancer	1.37e-05	7.24e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TGFB1—liver cancer	1.37e-05	7.23e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—HRAS—liver cancer	1.37e-05	7.22e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—KRAS—liver cancer	1.36e-05	7.2e-05	CbGpPWpGaD
Amoxapine—DRD2—GPCR downstream signaling—AKT1—liver cancer	1.36e-05	7.17e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	1.35e-05	7.13e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.35e-05	7.13e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CDKN1B—liver cancer	1.35e-05	7.12e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—HRAS—liver cancer	1.35e-05	7.1e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CASP3—liver cancer	1.35e-05	7.1e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CDKN1B—liver cancer	1.34e-05	7.09e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL2—liver cancer	1.34e-05	7.09e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—RAF1—liver cancer	1.34e-05	7.08e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—IL6—liver cancer	1.34e-05	7.06e-05	CbGpPWpGaD
Amoxapine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.34e-05	7.05e-05	CbGpPWpGaD
Amoxapine—HRH1—GPCR downstream signaling—AKT1—liver cancer	1.33e-05	7.04e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—PIK3CA—liver cancer	1.33e-05	7.04e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CG—liver cancer	1.33e-05	7.03e-05	CbGpPWpGaD
Amoxapine—CHRM1—GPCR downstream signaling—AKT1—liver cancer	1.33e-05	7.02e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TP53—liver cancer	1.33e-05	7.01e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TP53—liver cancer	1.33e-05	7e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CASP3—liver cancer	1.33e-05	6.99e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	1.32e-05	6.98e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL2—liver cancer	1.32e-05	6.98e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CASP3—liver cancer	1.32e-05	6.97e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL2—liver cancer	1.32e-05	6.96e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CASP3—liver cancer	1.32e-05	6.95e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—IL6—liver cancer	1.32e-05	6.94e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL2—liver cancer	1.32e-05	6.94e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—IL6—liver cancer	1.31e-05	6.93e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—PIK3CA—liver cancer	1.31e-05	6.93e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CCND1—liver cancer	1.31e-05	6.91e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	1.31e-05	6.91e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MTOR—liver cancer	1.31e-05	6.91e-05	CbGpPWpGaD
Amoxapine—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	1.31e-05	6.91e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—IL6—liver cancer	1.31e-05	6.91e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—JUN—liver cancer	1.31e-05	6.9e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—VEGFA—liver cancer	1.3e-05	6.87e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CTNNB1—liver cancer	1.3e-05	6.85e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CASP3—liver cancer	1.3e-05	6.84e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL2—liver cancer	1.3e-05	6.83e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.29e-05	6.83e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TP53—liver cancer	1.29e-05	6.81e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CCND1—liver cancer	1.29e-05	6.8e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—IL6—liver cancer	1.29e-05	6.8e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—STAT3—liver cancer	1.29e-05	6.8e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—JUN—liver cancer	1.29e-05	6.79e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CCND1—liver cancer	1.29e-05	6.79e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—KRAS—liver cancer	1.29e-05	6.79e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PPARG—liver cancer	1.29e-05	6.79e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—JUN—liver cancer	1.28e-05	6.77e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CCND1—liver cancer	1.28e-05	6.77e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.28e-05	6.76e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—JUN—liver cancer	1.28e-05	6.75e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.28e-05	6.74e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CTNNB1—liver cancer	1.27e-05	6.72e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MMP9—liver cancer	1.27e-05	6.71e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—HRAS—liver cancer	1.27e-05	6.7e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CTNNB1—liver cancer	1.27e-05	6.7e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TP53—liver cancer	1.27e-05	6.7e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—KRAS—liver cancer	1.27e-05	6.7e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—HRAS—liver cancer	1.27e-05	6.7e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CDKN1A—liver cancer	1.27e-05	6.69e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CCND1—liver cancer	1.26e-05	6.66e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—JUN—liver cancer	1.26e-05	6.65e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—PIK3CA—liver cancer	1.25e-05	6.61e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MMP9—liver cancer	1.25e-05	6.61e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	1.25e-05	6.6e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	1.25e-05	6.6e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MMP9—liver cancer	1.25e-05	6.59e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.25e-05	6.58e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MMP9—liver cancer	1.25e-05	6.57e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CDKN1A—liver cancer	1.25e-05	6.57e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CDKN1A—liver cancer	1.24e-05	6.55e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MAPK8—liver cancer	1.24e-05	6.53e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—HRAS—liver cancer	1.23e-05	6.51e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—AKT1—liver cancer	1.23e-05	6.51e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	1.23e-05	6.49e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MMP9—liver cancer	1.23e-05	6.47e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	1.22e-05	6.44e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.22e-05	6.42e-05	CbGpPWpGaD
Amoxapine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	1.22e-05	6.42e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—IL6—liver cancer	1.22e-05	6.41e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MAPK8—liver cancer	1.22e-05	6.41e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—HRAS—liver cancer	1.21e-05	6.41e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—IL6—liver cancer	1.21e-05	6.41e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.21e-05	6.41e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TP53—liver cancer	1.21e-05	6.4e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—AKT1—liver cancer	1.21e-05	6.39e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MAPK8—liver cancer	1.21e-05	6.39e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—AKT1—liver cancer	1.21e-05	6.37e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CASP3—liver cancer	1.21e-05	6.36e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL2—liver cancer	1.2e-05	6.35e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—IL6—liver cancer	1.2e-05	6.32e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MYC—liver cancer	1.2e-05	6.32e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TGFB1—liver cancer	1.19e-05	6.3e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MAPK8—liver cancer	1.19e-05	6.29e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MYC—liver cancer	1.19e-05	6.28e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—AKT1—liver cancer	1.19e-05	6.27e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.19e-05	6.27e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—PIK3CA—liver cancer	1.18e-05	6.24e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—IL6—liver cancer	1.18e-05	6.23e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CCND1—liver cancer	1.17e-05	6.19e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CD—liver cancer	1.17e-05	6.18e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—JUN—liver cancer	1.17e-05	6.18e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—PIK3CA—liver cancer	1.17e-05	6.15e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—IL6—liver cancer	1.16e-05	6.13e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	1.16e-05	6.13e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—HRAS—liver cancer	1.16e-05	6.12e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—ALB—liver cancer	1.16e-05	6.1e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TP53—liver cancer	1.14e-05	6.03e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—VEGFA—liver cancer	1.14e-05	6.03e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MMP9—liver cancer	1.14e-05	6.01e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	1.14e-05	5.99e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—STAT3—liver cancer	1.13e-05	5.97e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TP53—liver cancer	1.13e-05	5.95e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.12e-05	5.93e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—VEGFA—liver cancer	1.12e-05	5.92e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—AKT1—liver cancer	1.12e-05	5.92e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—AKT1—liver cancer	1.12e-05	5.91e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—VEGFA—liver cancer	1.12e-05	5.9e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—STAT3—liver cancer	1.11e-05	5.87e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—STAT3—liver cancer	1.11e-05	5.86e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—IL6—liver cancer	1.11e-05	5.86e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	1.11e-05	5.84e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—STAT3—liver cancer	1.11e-05	5.84e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—KRAS—liver cancer	1.11e-05	5.84e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	1.1e-05	5.83e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—VEGFA—liver cancer	1.1e-05	5.81e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—KRAS—liver cancer	1.1e-05	5.81e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—HRAS—liver cancer	1.09e-05	5.77e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—AKT1—liver cancer	1.09e-05	5.75e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—STAT3—liver cancer	1.09e-05	5.75e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—HRAS—liver cancer	1.08e-05	5.69e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—AKT1—liver cancer	1.07e-05	5.66e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MYC—liver cancer	1.05e-05	5.55e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TGFB1—liver cancer	1.05e-05	5.53e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—IL6—liver cancer	1.05e-05	5.52e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MYC—liver cancer	1.03e-05	5.46e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—IL6—liver cancer	1.03e-05	5.45e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MYC—liver cancer	1.03e-05	5.45e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.03e-05	5.44e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TGFB1—liver cancer	1.03e-05	5.43e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MYC—liver cancer	1.03e-05	5.43e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TGFB1—liver cancer	1.03e-05	5.41e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—AKT1—liver cancer	1.02e-05	5.4e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	1.02e-05	5.4e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CB—liver cancer	1.02e-05	5.39e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PIK3CA—liver cancer	1.02e-05	5.36e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MYC—liver cancer	1.01e-05	5.34e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—STAT3—liver cancer	1.01e-05	5.34e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	1.01e-05	5.33e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TGFB1—liver cancer	1.01e-05	5.33e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TP53—liver cancer	9.83e-06	5.19e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TP53—liver cancer	9.78e-06	5.16e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—KRAS—liver cancer	9.72e-06	5.12e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—AKT1—liver cancer	9.66e-06	5.09e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—KRAS—liver cancer	9.56e-06	5.04e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PIK3CA—liver cancer	9.56e-06	5.04e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—KRAS—liver cancer	9.54e-06	5.03e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—AKT1—liver cancer	9.53e-06	5.03e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—KRAS—liver cancer	9.51e-06	5.02e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MYC—liver cancer	9.41e-06	4.96e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—HRAS—liver cancer	9.41e-06	4.96e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	9.39e-06	4.95e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—KRAS—liver cancer	9.36e-06	4.94e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—HRAS—liver cancer	9.36e-06	4.94e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—IL6—liver cancer	9e-06	4.75e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—IL6—liver cancer	8.96e-06	4.72e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PIK3CA—liver cancer	8.93e-06	4.71e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	8.78e-06	4.63e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CA—liver cancer	8.76e-06	4.62e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CA—liver cancer	8.74e-06	4.61e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KRAS—liver cancer	8.7e-06	4.59e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TP53—liver cancer	8.63e-06	4.55e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	8.6e-06	4.54e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TP53—liver cancer	8.5e-06	4.48e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TP53—liver cancer	8.48e-06	4.47e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TP53—liver cancer	8.45e-06	4.46e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TP53—liver cancer	8.32e-06	4.39e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—AKT1—liver cancer	8.3e-06	4.38e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—AKT1—liver cancer	8.26e-06	4.36e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—HRAS—liver cancer	8.26e-06	4.36e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—HRAS—liver cancer	8.13e-06	4.29e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—HRAS—liver cancer	8.11e-06	4.28e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—HRAS—liver cancer	8.08e-06	4.26e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	7.99e-06	4.21e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—HRAS—liver cancer	7.96e-06	4.2e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL6—liver cancer	7.9e-06	4.17e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—AKT1—liver cancer	7.81e-06	4.12e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL6—liver cancer	7.78e-06	4.1e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL6—liver cancer	7.76e-06	4.09e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL6—liver cancer	7.74e-06	4.08e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TP53—liver cancer	7.73e-06	4.08e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL6—liver cancer	7.62e-06	4.02e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—HRAS—liver cancer	7.39e-06	3.9e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—AKT1—liver cancer	7.29e-06	3.85e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—AKT1—liver cancer	7.17e-06	3.78e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—AKT1—liver cancer	7.16e-06	3.78e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—AKT1—liver cancer	7.14e-06	3.76e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL6—liver cancer	7.08e-06	3.73e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—AKT1—liver cancer	7.03e-06	3.71e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—AKT1—liver cancer	6.53e-06	3.44e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CA—liver cancer	6.23e-06	3.28e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—AKT1—liver cancer	5.09e-06	2.68e-05	CbGpPWpGaD
